MedTrace Logo

Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence

NCT03015246 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2020-11-10

No results posted yet for this study

Summary

This research deals with behaviors that are part of opioid dependence. The purpose is to study how stress and medication dose can affect opioid drug use.

Conditions

Interventions

DRUG

Extended release morphine

Dose (tailored to each participant based on his/her pre-experimental opioid use amount) is administered in 3 divided daily doses.

DRUG

Buprenorphine/Naloxone low dose

Buprenorphine/Naloxone dose of 1.4/0.36 mg/day

DRUG

Buprenorphine/Naloxone moderate dose

Buprenorphine/Naloxone dose of 4.2/1.08 mg/day

DRUG

Buprenorphine/Naloxone high dose

Buprenorphine/Naloxone dose of 12.8/3.16 mg/day

DRUG

Active stressor

Yohimbine hydrochloride 60mg + Hydrocortisone 20mg tablet

DRUG

Placebo stressor

Lactose

Sponsors & Collaborators

  • Wayne State University

    lead OTHER

Principal Investigators

  • Mark Greenwald, PhD · Wayne State University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2020-06-30
Completion
2020-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03015246 on ClinicalTrials.gov